What Is Adipotide / FTPP?
Adipotide is an experimental peptidomimetic designed to damage the blood vessels supporting white adipose tissue. It is also called FTPP, Prohibitin-TP01 and, in some research papers, CKGGRAKDC-GG-D(KLAKLAK)2.
That mechanism makes Adipotide fundamentally different from established weight-management medicines. It does not imitate a gut hormone such as GLP-1, block fat absorption or directly increase metabolic rate. Its targeting segment was designed to recognise prohibitin on the surface of blood vessels in white fat. Its second segment was designed to disrupt mitochondria and trigger cell death after entering those vascular cells.
Mouse and obese-monkey experiments reported loss of white fat, lower body weight and improved metabolic measurements. The same primate programme also found predictable, dose-related changes in kidney proximal-tubule function. One first-in-human Phase I study opened in men with metastatic prostate cancer and obesity, enrolled four people, terminated at the principal investigator's request and posted no results.
What kind of molecule is Adipotide?
Adipotide is better described as a targeted pro-apoptotic peptidomimetic than as an ordinary signalling peptide. A peptidomimetic is a molecule built to imitate useful structural or functional features of a peptide, often with modifications that change stability or biological behaviour.
The construct has two functional parts:
- CKGGRAKDC, a nine-residue cyclic targeting motif selected for its tendency to home to blood vessels in white adipose tissue. The terminal cysteines form a disulphide bond that constrains the loop.
- D(KLAKLAK)2, a 14-residue amphipathic sequence made from D-amino acids. Once it reaches the interior of a target cell, this segment is intended to disrupt mitochondrial membranes and initiate apoptosis, the regulated process of cell death.
The two sections are connected through a glycine-glycine linker. The complete construct is sometimes shortened to FTPP, meaning fat-targeted pro-apoptotic peptide.
The targeting portion does not itself dissolve fat. The destructive portion is not inherently specific for adipose tissue. Selectivity depends on the complete construct finding the intended vascular marker, entering the relevant endothelial cells and delivering the mitochondrial-disrupting sequence without unacceptable exposure elsewhere.
Why target the blood supply to fat?
Adipose tissue is not an inert storage bag. It contains adipocytes, immune cells, connective tissue, nerves and a network of small blood vessels. As fat mass expands, its vascular system has to supply oxygen and nutrients and remove metabolic products.
The Adipotide strategy grew from tumour-vascular targeting research. Tumours depend on specialised blood vessels, so researchers explored whether molecular addresses on those vessels could deliver a destructive payload selectively. The same logic was applied to white fat: identify a surface marker associated with its vasculature, then use it as an address for a pro-apoptotic sequence.
This is a powerful experimental concept, but it also explains why the safety question is unusually serious. The intended pharmacology is cell killing. The key issue is not simply whether the molecule reaches fat; it is whether its targeting is selective enough to spare kidney, other vascular beds and other cells that express or handle the same proteins.
What is prohibitin?
Prohibitin usually refers to a highly conserved protein involved in mitochondrial organisation, stress responses and cellular signalling. It is widely expressed inside cells. The original Adipotide research proposed that prohibitin was also accessible on the surface of endothelial cells within white-fat vasculature, allowing the CKGGRAKDC sequence to bind there.
The 2004 mouse paper used in-vivo phage display to identify the targeting motif. Phage display exposes many peptide sequences on viruses that infect bacteria, allowing researchers to recover sequences that accumulate in a chosen tissue. The authors reported that CKGGRAKDC associated with prohibitin and homed to white-fat blood vessels.
Finding prohibitin in human white-fat vasculature supported the possibility of translation, but it did not prove that the entire construct would behave selectively in people. A protein can have different accessibility, abundance and binding partners across tissues, disease states and species. Receptor presence is therefore a starting condition, not clinical validation.
How does the cell-killing sequence work?
The D(KLAKLAK)2 segment is amphipathic, meaning different sides of its structure interact preferentially with water or lipids. It was designed to disrupt mitochondrial membranes after reaching the cell interior. Mitochondrial damage can release signals that activate apoptosis.
The D-amino-acid configuration makes the sequence less vulnerable to ordinary proteases than an equivalent chain of natural L-amino acids. That may preserve activity in the circulation and inside tissues, but greater resistance to breakdown is not automatically beneficial. It can also change exposure duration and the consequences of delivery outside the intended target.
Apoptosis of endothelial cells reduces the microvascular support available to nearby adipocytes. The animal research proposed that fat cells were then resorbed and metabolised. This differs from directly poisoning every adipocyte: the vascular compartment was the stated primary target.
How was Adipotide discovered and developed?
The development story is short and instructive.
| Period | Development |
|---|---|
| 2004 | Researchers reported that CKGGRAKDC targeted prohibitin in white-fat vasculature and that the linked pro-apoptotic construct reversed obesity in mice |
| 2011 | A controlled programme in obese rhesus monkeys reported reduced fat, body weight and insulin resistance, alongside reversible kidney proximal-tubule effects |
| 2012 | Independent mouse work reported rapid improvement in glucose tolerance; a published comment challenged whether reduced food intake contributed more to the primate weight loss than the proposed vascular mechanism |
| 2012 | A first participant entered a Phase I study of Prohibitin-TP01 in men with metastatic prostate cancer and obesity |
| 2019 | The registry was updated to show the trial terminated after four participants, with no results posted |
| Current position | No published human outcome data, no Phase II or Phase III programme and no approved product |
Early commercial announcements described Adipotide as an anti-obesity candidate. The human study nevertheless enrolled men with advanced prostate cancer. That setting reflected both the origin of the technology in oncology and the ethics of first exposing people to an experimental cell-killing construct. It was not a successful obesity trial.
What did the original mouse study find?
The 2004 Nature Medicine paper tested the targeted construct in obese mouse models. The researchers reported destruction of white-fat vasculature, resorption of established white adipose tissue and substantial reversal of obesity. Metabolic measurements also moved towards those observed in leaner animals.
The study included targeting controls to distinguish the complete conjugate from its separate components. This matters because a mitochondrial-disrupting peptide without effective delivery should not be assumed to reach the same cells, while a targeting peptide without a destructive payload should not cause the same ablation.
The work established proof of concept in rodents. It did not establish that prohibitin would provide the same selectivity in humans, that repeated vascular ablation would remain safe or that weight loss would persist after treatment stopped.
What did the obese-monkey study find?
The 2011 Science Translational Medicine paper is the main source behind online claims about Adipotide. Non-human primates are more informative than mice for some aspects of metabolism, body composition and kidney physiology, but they remain an animal model.
The programme included dose-finding work and a controlled fixed-dose experiment. In the fixed-dose study, ten obese rhesus monkeys received Adipotide and five received saline for 28 days. The paper reported average reductions of:
- 10.6% in body weight
- 10.0% in body-mass index
- 8.4% in abdominal circumference
Magnetic resonance imaging and dual-energy X-ray absorptiometry supported a reduction in fat rather than simple dehydration or measurement error. Insulin resistance improved, while lean animals did not show the same weight-loss response in the broader programme.
Those results were striking enough to justify cautious translational interest. They did not show durable weight management. During the four-week recovery period, the decreases in body weight, BMI and abdominal circumference began to reverse. A treatment that temporarily removes fat but does not alter the drivers of weight regain may require repeated exposure, which would make cumulative safety particularly important.
Food intake also fell in treated animals. The investigators interpreted the overall findings as targeted loss of white adipose tissue, but reduced intake could contribute to weight change. A later published comment argued that appetite effects might explain more of the result than the paper acknowledged. The authors replied, and later mouse work attempted to separate metabolic effects from food intake and weight loss.
What happened to insulin sensitivity?
The primate study reported improved insulin resistance alongside fat loss. Removing dysfunctional visceral fat could plausibly improve glucose handling, but the experiment cannot establish whether the change arose from lower fat mass, reduced food intake, direct vascular signalling or several mechanisms together.
A separate 2012 mouse study examined glucose tolerance very early in treatment. Glucose handling improved within two to three days, before substantial weight loss, and the comparison included pair-fed animals. Serum insulin and triglycerides were lower, while gene-expression and metabolite patterns changed in adipose tissue.
That finding suggested that adipose vasculature may influence glucose regulation before the scales change. It remains a mouse experiment. It does not show that Adipotide treats type 2 diabetes in humans, and no human trial has reported HbA1c, glucose tolerance or diabetes outcomes.
Why is kidney toxicity central to the evidence?
The primate paper reported predictable and reversible changes in renal proximal-tubule function at the experimentally determined optimal exposures. The proximal tubule is a metabolically active part of the nephron that reabsorbs filtered substances. Injury there can cause urinary loss of molecules that would normally be reclaimed and can alter kidney-function markers.
The authors described the changes as dose dependent and reversible after treatment ended. Reversibility in a small animal programme is more reassuring than progressive permanent injury, but it is not proof of human safety. It establishes the kidney as an organ of concern.
There are several reasons the signal matters:
- The proposed therapy might require repeated courses if weight returns.
- People with obesity may already have diabetes, hypertension or kidney vulnerability.
- D-amino-acid peptides can have different degradation and renal-handling characteristics from ordinary peptides.
- There is no published human pharmacokinetic or renal-safety dataset to define a margin between desired and harmful exposure.
Descriptions of Adipotide that mention the monkey weight loss but omit the renal findings give a distorted account of the same experiment.
Was Adipotide tested in humans?
Exposure occurred in one registered first-in-human trial, but no human findings have been published.
ClinicalTrials.gov record NCT01262664 describes a Phase I, open-label study titled “A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity.” The investigational product was listed as Prohibitin-TP01.
The study was designed to investigate safety, tolerability, pharmacokinetics, a maximum tolerated dose and biological activity during a single 28-day cycle. It planned to enrol substantially more people but recorded an actual enrolment of four. The registry lists the status as terminated and gives the reason as “Terminated per PI's request.” No results are posted.
This record supports only a few narrow conclusions:
- At least four participants entered the study.
- The study did not complete as planned.
- The public record does not say what happened to their weight, cancer, kidneys or other safety measures.
- A registered starting exposure is not an established safe or effective dose.
It is inaccurate to call Adipotide completely untested in humans. It is equally inaccurate to claim human evidence for weight loss or safety. The correct statement is that limited human exposure occurred in a terminated trial whose outcomes remain unreported.
Why were prostate-cancer patients enrolled?
The trial enrolled men with metastatic or otherwise incurable prostate cancer who also met an obesity criterion. Adipose tissue produces hormones and signalling molecules that can interact with cancer biology, and the technology came from vascular-targeted oncology research.
More importantly, a first-in-human study of a pro-apoptotic construct raises a different ethical balance from an ordinary weight-management trial. Investigators often begin cytotoxic or vascular-targeting agents in patients with serious disease and limited options rather than healthy volunteers.
That design means any unpublished experience could not simply be transferred to the wider population seeking fat loss. Advanced cancer, concurrent treatments and organ function can all affect tolerability and metabolism.
How is Adipotide synthesised and characterised?
The two peptide domains can be assembled using solid-phase peptide synthesis. The process must control sequence, the D-configuration of the KLAKLAK residues, formation of the cysteine disulphide bridge and attachment of the glycine linker.
A credible analytical package would need more than a single “purity” percentage. Relevant tests include:
- intact mass and sequence-sensitive confirmation
- chiral or otherwise stereochemistry-sensitive control of D-amino-acid residues
- confirmation of the intended disulphide-bonded cyclic targeting loop
- chromatographic analysis of truncated, deletion, oxidised and mispaired products
- peptide content adjusted for water and counterions
- a functional assay of binding or cell activity
- stability testing under defined storage and formulation conditions
For a sterile investigational product, endotoxin, sterility, particles, concentration accuracy and container integrity are separate requirements. A vendor chromatogram cannot establish clinical equivalence to Prohibitin-TP01, and no approved reference product exists against which an online vial can be treated as a generic.
Is Adipotide the same as ordinary weight-loss medication?
No. Modern approved obesity medicines generally act through defined hormonal or neural pathways and have large randomised programmes measuring weight, adverse events and cardiometabolic outcomes. Adipotide was designed to ablate part of a tissue's vasculature.
The monkey result cannot be compared directly with percentages from human obesity trials. Species, sample size, duration, study design, body-composition methods and safety monitoring differ. Most importantly, the Adipotide number is an animal result rather than an estimate of treatment effect in people.
The absence of human evidence also prevents a meaningful benefit-risk comparison. A dramatic animal effect does not compensate for missing human safety, dose-ranging and durability data.
Is Adipotide approved or legally marketed as a medicine?
Adipotide is not approved by the US Food and Drug Administration, the UK Medicines and Healthcare products Regulatory Agency or the European Medicines Agency. No authorised indication, licensed formulation or approved product label exists.
“Research use only” is a supplier description, not a regulatory approval and not evidence that a product is suitable for human administration. Compounded drugs are not FDA approved, and the agency does not review them for safety, effectiveness or quality before marketing. That general point does not mean every compounded product is unlawful; it means compounding cannot substitute for an Adipotide approval programme that never produced public human results.
How strong is the evidence overall?
| Question | Best available evidence | Defensible conclusion |
|---|---|---|
| Does the targeting construct reduce white fat? | Controlled mouse and obese-primate experiments | Yes in the studied animal models |
| Did obese monkeys lose weight? | Ten treated and five control rhesus monkeys in the fixed-dose experiment | A substantial 28-day reduction was reported, followed by early regain |
| Does it improve glucose control? | Mouse experiments and metabolic measurements in monkeys | Preclinical signals exist; no human diabetes benefit is established |
| Is kidney injury a concern? | Dose-related proximal-tubule changes across monkey species | Yes; reversibility in animals does not establish a human safety margin |
| Does it cause weight loss in people? | No reported human outcome data | Unknown |
| Is there a safe human dose? | Terminated four-participant Phase I trial with no posted results | Unknown |
| Is it an approved obesity medicine? | No regulatory approval | No |
The research established a provocative biological strategy, not a usable human therapy. The missing step is not another mouse experiment. It is a transparent clinical programme capable of defining pharmacokinetics, organ toxicity, dose response, body-composition change and durability.
What claims are not established?
Adipotide has not been shown in people to produce fat loss, preserve muscle, improve insulin sensitivity, target visceral fat selectively or maintain weight loss. It has not established a safe cycle, repeat-treatment strategy or kidney-monitoring protocol.
No published evidence validates combinations with GLP-1 medicines, growth-hormone secretagogues, exercise programmes or other research peptides. Combining interventions would make causality and safety harder to interpret, not compensate for the missing human data.
Frequently asked questions
Is Adipotide a peptide?
It is a synthetic two-part peptidomimetic made from a cyclic targeting peptide joined to a D-amino-acid pro-apoptotic sequence.
What does FTPP mean?
FTPP means fat-targeted pro-apoptotic peptide.
What is Prohibitin-TP01?
It is the development name used for the investigational product in the only registered first-in-human study.
How is Adipotide supposed to work?
Its targeting sequence is intended to bind prohibitin on blood vessels serving white fat. The attached D(KLAKLAK)2 sequence then disrupts mitochondria in endothelial cells and promotes apoptosis.
Did Adipotide make monkeys lose weight?
Yes. In one 28-day controlled experiment, ten treated obese rhesus monkeys lost an average 10.6% of body weight. This is an animal result, and some weight began returning after treatment.
Has Adipotide produced weight loss in humans?
No published or posted human result establishes this. The only registered human trial enrolled four participants, terminated and reported no outcomes.
Why is Adipotide associated with kidney risk?
The primate programme reported dose-related changes in renal proximal-tubule function across three monkey species. The authors described them as reversible, but no human safety margin is known.
Does Adipotide reduce appetite?
Food intake fell in the primate study, creating debate about how much of the weight loss came from targeted fat-vascular damage versus reduced eating. No human appetite data are available.
Is Adipotide FDA approved?
No. It is not an FDA-approved medicine for obesity, cancer or any other condition.
Is an online research product equivalent to the clinical material?
No equivalence has been demonstrated. Identity, stereochemistry, disulphide formation, impurities, content, sterility, endotoxin and stability would all need appropriate testing.
Why did the human trial involve prostate cancer?
The technology originated in vascular-targeting research, adipose signalling may interact with cancer biology, and first exposure to a pro-apoptotic construct was studied in people with serious disease rather than routine weight-management patients.
Did the human trial show that Adipotide was unsafe?
The public record does not answer that question. It says the trial terminated at the principal investigator's request after four participants, but no results were posted.
Is the monkey weight-loss percentage comparable with human drug trials?
No. Different species, samples, durations and designs make a direct comparison misleading.
Could Adipotide be used repeatedly if weight returns?
No repeat-treatment safety or efficacy programme has established this. Early weight regain in monkeys makes the absence of cumulative kidney-safety data especially important.
What would convincing future research require?
A credible restart would need a fully characterised product, non-clinical toxicology addressing kidney exposure, careful first-in-human pharmacokinetics and transparent reporting of every serious adverse event. Later controlled studies would need to distinguish loss of fat from water or lean tissue and to measure durability after treatment stops.
The programme would also need to show why destroying adipose vasculature offers an acceptable advantage over established therapies. That requires comparison of clinically meaningful outcomes and risks, not just a striking short-term percentage on a scale.
The bottom line
Adipotide is scientifically interesting because it treats the blood supply to white fat as a molecular target. Mouse and monkey experiments showed that the construct could reduce adiposity, and the primate study reported substantial short-term weight loss.
The same evidence also identified kidney proximal-tubule effects and early weight regain. Human development never produced a public result: four people entered a Phase I cancer study, the trial terminated and no outcomes were reported.
That leaves Adipotide as a preclinical concept with limited, opaque human exposure rather than an evidence-based weight-loss treatment. Its mechanism is not merely experimental; it is intentionally destructive, making product identity, tissue selectivity and organ safety central rather than secondary concerns.
Research notice
This guide describes research and regulatory information. It does not provide dosing, administration, cycling, purchasing or self-experimentation guidance.
Sources
Research reviewed through October 2026.